1
|
Li W, Gonzalez KM, Chung J, Kim M, Lu J. Surface-modified nanotherapeutics targeting atherosclerosis. Biomater Sci 2022; 10:5459-5471. [PMID: 35980230 PMCID: PMC9529904 DOI: 10.1039/d2bm00660j] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Atherosclerosis is a chronic and metabolic-related disease that is a serious threat to human health. Currently available diagnostic and therapeutic measures for atherosclerosis lack adequate efficiency which requires promising alternative approaches. Nanotechnology-based nano-delivery systems allow for new perspectives for atherosclerosis therapy. Surface-modified nanoparticles could achieve highly effective therapeutic effects by binding to specific receptors that are abnormally overexpressed in atherosclerosis, with less adverse effects on non-target tissues. The main purpose of this review is to summarize the research progress and design ideas to target atherosclerosis using a variety of ligand-modified nanoparticle systems, discuss the shortcomings of current vector design, and look at future development directions. We hope that this review will provide novel research strategies for the design and development of nanotherapeutics targeting atherosclerosis.
Collapse
Affiliation(s)
- Wenpan Li
- Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, Arizona, 85721, USA.
| | - Karina Marie Gonzalez
- Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, Arizona, 85721, USA.
| | - Jinha Chung
- Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, Arizona, 85721, USA.
| | - Minhyeok Kim
- Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, Arizona, 85721, USA.
| | - Jianqin Lu
- Skaggs Pharmaceutical Sciences Center, Department of Pharmacology & Toxicology, R. Ken Coit College of Pharmacy, The University of Arizona, Tucson, Arizona, 85721, USA.
- NCI-designated University of Arizona Comprehensive Cancer Center, Tucson, Arizona, 85721, USA
- BIO5 Institute, The University of Arizona, Tucson, Arizona, 85721, USA
- Southwest Environmental Health Sciences Center, The University of Arizona, Tucson, 85721, USA
| |
Collapse
|
2
|
Vu MN, Kelly HG, Wheatley AK, Peng S, Pilkington EH, Veldhuis NA, Davis TP, Kent SJ, Truong NP. Cellular Interactions of Liposomes and PISA Nanoparticles during Human Blood Flow in a Microvascular Network. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2020; 16:e2002861. [PMID: 32583981 PMCID: PMC7361276 DOI: 10.1002/smll.202002861] [Citation(s) in RCA: 60] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 06/04/2020] [Indexed: 05/21/2023]
Abstract
A key concept in nanomedicine is encapsulating therapeutic or diagnostic agents inside nanoparticles to prolong blood circulation time and to enhance interactions with targeted cells. During circulation and depending on the selected application (e.g., cancer drug delivery or immune modulators), nanoparticles are required to possess low or high interactions with cells in human blood and blood vessels to minimize side effects or maximize delivery efficiency. However, analysis of cellular interactions in blood vessels is challenging and is not yet realized due to the diverse components of human blood and hemodynamic flow in blood vessels. Here, the first comprehensive method to analyze cellular interactions of both synthetic and commercially available nanoparticles under human blood flow conditions in a microvascular network is developed. Importantly, this method allows to unravel the complex interplay of size, charge, and type of nanoparticles on their cellular associations under the dynamic flow of human blood. This method offers a unique platform to study complex interactions of any type of nanoparticles in human blood flow conditions and serves as a useful guideline for the rational design of liposomes and polymer nanoparticles for diverse applications in nanomedicine.
Collapse
Affiliation(s)
- Mai N. Vu
- Australian Research Council Centre of Excellence in Convergent Bio‐Nano Science and TechnologyParkvilleVIC3052Australia
- Monash Institute of Pharmaceutical SciencesMonash UniversityParkvilleVIC3052Australia
- Peter Doherty Institute for Infection and ImmunityDepartment of Microbiology and ImmunologyUniversity of MelbourneMelbourneVIC3000Australia
- Department of PharmaceuticsHanoi University of PharmacyHanoi10000Vietnam
| | - Hannah G. Kelly
- Australian Research Council Centre of Excellence in Convergent Bio‐Nano Science and TechnologyParkvilleVIC3052Australia
- Peter Doherty Institute for Infection and ImmunityDepartment of Microbiology and ImmunologyUniversity of MelbourneMelbourneVIC3000Australia
| | - Adam K. Wheatley
- Australian Research Council Centre of Excellence in Convergent Bio‐Nano Science and TechnologyParkvilleVIC3052Australia
- Peter Doherty Institute for Infection and ImmunityDepartment of Microbiology and ImmunologyUniversity of MelbourneMelbourneVIC3000Australia
| | - Scott Peng
- Australian Research Council Centre of Excellence in Convergent Bio‐Nano Science and TechnologyParkvilleVIC3052Australia
- Monash Institute of Pharmaceutical SciencesMonash UniversityParkvilleVIC3052Australia
| | - Emily H. Pilkington
- Australian Research Council Centre of Excellence in Convergent Bio‐Nano Science and TechnologyParkvilleVIC3052Australia
- Monash Institute of Pharmaceutical SciencesMonash UniversityParkvilleVIC3052Australia
- Peter Doherty Institute for Infection and ImmunityDepartment of Microbiology and ImmunologyUniversity of MelbourneMelbourneVIC3000Australia
| | - Nicholas A. Veldhuis
- Australian Research Council Centre of Excellence in Convergent Bio‐Nano Science and TechnologyParkvilleVIC3052Australia
- Monash Institute of Pharmaceutical SciencesMonash UniversityParkvilleVIC3052Australia
| | - Thomas P. Davis
- Australian Research Council Centre of Excellence in Convergent Bio‐Nano Science and TechnologyParkvilleVIC3052Australia
- Monash Institute of Pharmaceutical SciencesMonash UniversityParkvilleVIC3052Australia
- Australia Institute of Bioengineering & NanotechnologyUniversity of QueenslandBrisbaneQLD4072Australia
| | - Stephen J. Kent
- Australian Research Council Centre of Excellence in Convergent Bio‐Nano Science and TechnologyParkvilleVIC3052Australia
- Peter Doherty Institute for Infection and ImmunityDepartment of Microbiology and ImmunologyUniversity of MelbourneMelbourneVIC3000Australia
- Melbourne Sexual Health Centre and Department of Infectious DiseasesAlfred Hospital and Central Clinical SchoolMonash UniversityMelbourneVIC3004Australia
| | - Nghia P. Truong
- Australian Research Council Centre of Excellence in Convergent Bio‐Nano Science and TechnologyParkvilleVIC3052Australia
- Monash Institute of Pharmaceutical SciencesMonash UniversityParkvilleVIC3052Australia
| |
Collapse
|
3
|
Haemocompatibility of Modified Nanodiamonds. MATERIALS 2017; 10:ma10040352. [PMID: 28772710 PMCID: PMC5506996 DOI: 10.3390/ma10040352] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/22/2016] [Revised: 03/21/2017] [Accepted: 03/23/2017] [Indexed: 12/17/2022]
Abstract
This study reports the interactions of modified nanodiamond particles in vitro with human blood. Modifications performed on the nanodiamond particles include oxygenation with a chemical method and hydrogenation upon chemical vapor deposition (CVD) plasma treatment. Such nanodiamonds were later incubated in whole human blood for different time intervals, ranging from 5 min to 5 h. The morphology of red blood cells was assessed along with spectral measurements and determination of haemolysis. The results showed that no more than 3% of cells were affected by the nanodiamonds. Specific modifications of the nanodiamonds give us the possibility to obtain nanoparticles which are biocompatible with human blood. They can form a basis for the development of nanoscale biomarkers and parts of sensing systems and devices useful in biomedical environments.
Collapse
|
4
|
Namdari M, Cheraghi M, Negahdari B, Eatemadi A, Daraee H. Recent advances in magnetoliposome for heart drug delivery. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2017; 45:1-7. [PMID: 28272903 DOI: 10.1080/21691401.2017.1299159] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Magnetic nanoparticles (NPs) also have been subject of interest to the therapeutic and imaging field because of their unique magnetic properties. Magnetoliposomes (MLs) are made up of a combination of liposomes and magnetic NPs, and they have been proven to be a potential biomaterial to fields like magnetic-targeted drug delivery, MRI, etc. The efficiency of a drug delivery system to the heart determines the treatment strategy for most of the heart diseases. In this review article, we summarize the recent development and updates in the application of MLs as a drug delivery system for heart/cardiac diseases.
Collapse
Affiliation(s)
- Mehrdad Namdari
- a Department of Cardiology , Lorestan University of Medical Sciences , Khoramabad , Iran
| | - Mostafa Cheraghi
- a Department of Cardiology , Lorestan University of Medical Sciences , Khoramabad , Iran
| | - Babak Negahdari
- b Department of Medical Biotechnology , School of advanced Technologies in Medicine, Tehran University of Medical Sciences , Tehran , Iran
| | - Ali Eatemadi
- b Department of Medical Biotechnology , School of advanced Technologies in Medicine, Tehran University of Medical Sciences , Tehran , Iran.,c Department of Medical Biotechnology , School of Medicine, Lorestan University of Medical Sciences , Khoramabad , Iran
| | - Hadis Daraee
- b Department of Medical Biotechnology , School of advanced Technologies in Medicine, Tehran University of Medical Sciences , Tehran , Iran.,c Department of Medical Biotechnology , School of Medicine, Lorestan University of Medical Sciences , Khoramabad , Iran
| |
Collapse
|
5
|
Affiliation(s)
- Yuqi Zhang
- Joint
Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695, United States
- Center
for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics,
UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
- Department
of Mechanical and Aerospace Engineering, North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Jicheng Yu
- Joint
Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695, United States
- Center
for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics,
UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
| | - Hunter N. Bomba
- Joint
Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Yong Zhu
- Joint
Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695, United States
- Department
of Mechanical and Aerospace Engineering, North Carolina State University, Raleigh, North Carolina 27695, United States
| | - Zhen Gu
- Joint
Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina 27695, United States
- Center
for Nanotechnology in Drug Delivery and Division of Molecular Pharmaceutics,
UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
- Department
of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States
| |
Collapse
|
6
|
Di Mauro V, Iafisco M, Salvarani N, Vacchiano M, Carullo P, Ramírez-Rodríguez GB, Patrício T, Tampieri A, Miragoli M, Catalucci D. Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs. Nanomedicine (Lond) 2016; 11:891-906. [DOI: 10.2217/nnm.16.26] [Citation(s) in RCA: 71] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Aim: To develop biocompatible and bioresorbable negatively charged calcium phosphate nanoparticles (CaP-NPs) as an innovative therapeutic system for the delivery of bioactive molecules to the heart. Materials & methods: CaP-NPs were synthesized via a straightforward one-pot biomineralization-inspired protocol employing citrate as a stabilizing agent and regulator of crystal growth. CaP-NPs were administered to cardiac cells in vitro and effects of treatments were assessed. CaP-NPs were administered in vivo and delivery of microRNAs was evaluated. Results: CaP-NPs efficiently internalized into cardiomyocytes without promoting toxicity or interfering with any functional properties. CaP-NPs successfully encapsulated synthetic microRNAs, which were efficiently delivered into cardiac cells in vitro and in vivo. Conclusion: CaP-NPs are a safe and efficient drug-delivery system for potential therapeutic treatments of polarized cells such as cardiomyocytes.
Collapse
Affiliation(s)
- Vittoria Di Mauro
- National Research Council (CNR), Institute of Genetics & Biomedical Research, Milan Unit, Milan 20138, Italy
- Humanitas Clinical & Research Center, Rozzano (MI) 20089, Italy
| | - Michele Iafisco
- National Research Council (CNR), Institute of Science & Technology for Ceramics (ISTEC) 48018 Faenza (RA), Italy
| | - Nicolò Salvarani
- National Research Council (CNR), Institute of Genetics & Biomedical Research, Milan Unit, Milan 20138, Italy
- Humanitas Clinical & Research Center, Rozzano (MI) 20089, Italy
| | - Marco Vacchiano
- National Research Council (CNR), Institute of Genetics & Biomedical Research, Milan Unit, Milan 20138, Italy
| | - Pierluigi Carullo
- National Research Council (CNR), Institute of Genetics & Biomedical Research, Milan Unit, Milan 20138, Italy
- Humanitas Clinical & Research Center, Rozzano (MI) 20089, Italy
| | | | - Tatiana Patrício
- National Research Council (CNR), Institute of Science & Technology for Ceramics (ISTEC) 48018 Faenza (RA), Italy
| | - Anna Tampieri
- National Research Council (CNR), Institute of Science & Technology for Ceramics (ISTEC) 48018 Faenza (RA), Italy
| | - Michele Miragoli
- National Research Council (CNR), Institute of Genetics & Biomedical Research, Milan Unit, Milan 20138, Italy
- Humanitas Clinical & Research Center, Rozzano (MI) 20089, Italy
| | - Daniele Catalucci
- National Research Council (CNR), Institute of Genetics & Biomedical Research, Milan Unit, Milan 20138, Italy
- Humanitas Clinical & Research Center, Rozzano (MI) 20089, Italy
| |
Collapse
|
7
|
Chung EJ, Tirrell M. Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis. Adv Healthc Mater 2015; 4:2408-22. [PMID: 26085109 PMCID: PMC4760622 DOI: 10.1002/adhm.201500126] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Revised: 03/31/2015] [Indexed: 01/03/2023]
Abstract
Self-assembling nanoparticles functionalized with targeting moieties have significant potential for atherosclerosis nanomedicine. While self-assembly allows the easy construction (and degradation) of nanoparticles with therapeutic or diagnostic functionality, or both, the targeting agent can direct them to a specific molecular marker within a given stage of the disease. Therefore, supramolecular nanoparticles have been investigated in the last decade as molecular imaging agents or explored as nanocarriers that can decrease the systemic toxicity of drugs by producing accumulation predominantly in specific tissues of interest. In this Progress Report, the pathogenesis of atherosclerosis and the damage caused to vascular tissue are described, as well as the current diagnostic and treatment options. An overview of targeted strategies using self-assembling nanoparticles is provided, including liposomes, high density lipoproteins, protein cages, micelles, proticles, and perfluorocarbon nanoparticles. Finally, an overview is given of current challenges, limitations, and future applications for personalized medicine in the context of atherosclerosis of self-assembling nanoparticles.
Collapse
Affiliation(s)
- Eun Ji Chung
- Institute for Molecular Engineering, University of Chicago, 5747 S.
Ellis Ave., Chicago, IL, 60637, USA
| | - Matthew Tirrell
- Institute for Molecular Engineering, University of Chicago, 5747 S.
Ellis Ave., Chicago, IL, 60637, USA
| |
Collapse
|
8
|
Uludağ H. Grand challenges in biomaterials. Front Bioeng Biotechnol 2014; 2:43. [PMID: 25368868 PMCID: PMC4202113 DOI: 10.3389/fbioe.2014.00043] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2014] [Accepted: 10/02/2014] [Indexed: 11/13/2022] Open
|
9
|
Chen HC, Qiu JT, Yang FL, Liu YC, Chen MC, Tsai RY, Yang HW, Lin CY, Lin CC, Wu TS, Tu YM, Xiao MC, Ho CH, Huang CC, Lai CS, Hua MY. Magnetic-Composite-Modified Polycrystalline Silicon Nanowire Field-Effect Transistor for Vascular Endothelial Growth Factor Detection and Cancer Diagnosis. Anal Chem 2014; 86:9443-50. [DOI: 10.1021/ac5001898] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Affiliation(s)
- Hsiao-Chien Chen
- Department
of Chemical and Materials Engineering and Biosensor Group, Biomedical Engineering Research Center, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
- Department
of Biochemistry, School of Medicine, Taipei Medical University, Taipei 11031, Taiwan, Republic of China
| | - Jian-Tai Qiu
- Department
of Biomedical Sciences, School of Medicine, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
- Department
of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taoyuan 33302, Taiwan, Republic of China
| | - Fu-Liang Yang
- National Nano Device Laboratories, Hsinchu Science Park, Hsinchu 30078, Taiwan, Republic of China
| | - Yin-Chih Liu
- Department
of Chemical and Materials Engineering and Biosensor Group, Biomedical Engineering Research Center, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
| | - Min-Cheng Chen
- National Nano Device Laboratories, Hsinchu Science Park, Hsinchu 30078, Taiwan, Republic of China
| | - Rung-Ywan Tsai
- Electronics
and Optoelectronics Research Laboratories, Industrial Technology Research Institute, Hsinchu 31040, Taiwan, Republic of China
| | - Hung-Wei Yang
- Department
of Chemical and Materials Engineering and Biosensor Group, Biomedical Engineering Research Center, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
| | - Chia-Yi Lin
- National Nano Device Laboratories, Hsinchu Science Park, Hsinchu 30078, Taiwan, Republic of China
| | - Chu-Chi Lin
- Department
of Biomedical Sciences, School of Medicine, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
- Department
of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taoyuan 33302, Taiwan, Republic of China
| | - Tzong-Shoon Wu
- Department
of Biomedical Sciences, School of Medicine, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
- Department
of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taoyuan 33302, Taiwan, Republic of China
| | - Yi-Ming Tu
- Department
of Chemical and Materials Engineering and Biosensor Group, Biomedical Engineering Research Center, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
| | - Min-Cong Xiao
- Department
of Chemical and Materials Engineering and Biosensor Group, Biomedical Engineering Research Center, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
| | - Chia-Hua Ho
- National Nano Device Laboratories, Hsinchu Science Park, Hsinchu 30078, Taiwan, Republic of China
| | - Chien-Chao Huang
- National Nano Device Laboratories, Hsinchu Science Park, Hsinchu 30078, Taiwan, Republic of China
| | - Chao-Sung Lai
- Department
of Electronic Engineering and Biosensor Group,
Biomedical Engineering Research Center, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
| | - Mu-Yi Hua
- Department
of Chemical and Materials Engineering and Biosensor Group, Biomedical Engineering Research Center, Chang Gung University, Taoyuan 33302, Taiwan, Republic of China
| |
Collapse
|
10
|
Bruckman M, Jiang K, Simpson EJ, Randolph LN, Luyt LG, Yu X, Steinmetz NF. Dual-modal magnetic resonance and fluorescence imaging of atherosclerotic plaques in vivo using VCAM-1 targeted tobacco mosaic virus. NANO LETTERS 2014; 14:1551-8. [PMID: 24499194 PMCID: PMC4169141 DOI: 10.1021/nl404816m] [Citation(s) in RCA: 96] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/29/2013] [Revised: 02/02/2014] [Indexed: 05/04/2023]
Abstract
The underlying cause of major cardiovascular events, such as myocardial infarctions and strokes, is atherosclerosis. For accurate diagnosis of this inflammatory disease, molecular imaging is required. Toward this goal, we sought to develop a nanoparticle-based, high aspect ratio, molecularly targeted magnetic resonance (MR) imaging contrast agent. Specifically, we engineered the plant viral nanoparticle platform tobacco mosaic virus (TMV) to target vascular cell adhesion molecule (VCAM)-1, which is highly expressed on activated endothelial cells at atherosclerotic plaques. To achieve dual optical and MR imaging in an atherosclerotic ApoE(-/-) mouse model, TMV was modified to carry near-infrared dyes and chelated Gd ions. Our results indicate molecular targeting of atherosclerotic plaques. On the basis of the multivalency and multifunctionality, the targeted TMV-based MR probe increased the detection limit significantly; the injected dose of Gd ions could be further reduced 400x compared to the suggested clinical use, demonstrating the utility of targeted nanoparticle cargo delivery.
Collapse
Affiliation(s)
- Michael
A. Bruckman
- Department of Biomedical Engineering, Department of Radiology, Department of Materials
Science and Engineering, and Department of Macromolecular Engineering, Case Western Reserve University Schools of Medicine
and Engineering, 10900
Euclid Avenue, Cleveland, Ohio 44106, United
States
| | - Kai Jiang
- Department of Biomedical Engineering, Department of Radiology, Department of Materials
Science and Engineering, and Department of Macromolecular Engineering, Case Western Reserve University Schools of Medicine
and Engineering, 10900
Euclid Avenue, Cleveland, Ohio 44106, United
States
| | - Emily J. Simpson
- Departments
of Chemistry, Oncology, Medical Imaging, The University of Western Ontario, London, Ontario N6A 4L6, Canada
| | - Lauren N. Randolph
- Department of Biomedical Engineering, Department of Radiology, Department of Materials
Science and Engineering, and Department of Macromolecular Engineering, Case Western Reserve University Schools of Medicine
and Engineering, 10900
Euclid Avenue, Cleveland, Ohio 44106, United
States
| | - Leonard G. Luyt
- Departments
of Chemistry, Oncology, Medical Imaging, The University of Western Ontario, London, Ontario N6A 4L6, Canada
| | - Xin Yu
- Department of Biomedical Engineering, Department of Radiology, Department of Materials
Science and Engineering, and Department of Macromolecular Engineering, Case Western Reserve University Schools of Medicine
and Engineering, 10900
Euclid Avenue, Cleveland, Ohio 44106, United
States
| | - Nicole F. Steinmetz
- Department of Biomedical Engineering, Department of Radiology, Department of Materials
Science and Engineering, and Department of Macromolecular Engineering, Case Western Reserve University Schools of Medicine
and Engineering, 10900
Euclid Avenue, Cleveland, Ohio 44106, United
States
| |
Collapse
|
11
|
Naghavi N, de Mel A, Alavijeh OS, Cousins BG, Seifalian AM. Nitric oxide donors for cardiovascular implant applications. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2013; 9:22-35. [PMID: 23136136 DOI: 10.1002/smll.201200458] [Citation(s) in RCA: 114] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/01/2012] [Revised: 06/13/2012] [Indexed: 06/01/2023]
Abstract
In an era of increased cardiovascular disease burden in the ageing population, there is great demand for devices that come in to contact with the blood such as heart valves, stents, and bypass grafts that offer life saving treatments. Nitric oxide (NO) elution from healthy endothelial tissue that lines the vessels maintains haemostasis throughout the vasculature. Surgical devices that release NO are desirable treatment options and N-diazeniumdiolates and S-nitrosothiols are recognized as preferred donor molecules. There is a keen interest to investigate newer methods by which NO donors can be retained within biomaterials so that their release and kinetic profiles can be optimized. A range of polymeric scaffolds incorporating microparticles and nanomaterials are presenting solutions to current challenges, and have been investigated in a range of clinical applications. This review outlines the application of NO donors for cardiovascular therapy using biomaterials that release NO locally to prevent thrombosis and intimal hyperplasia (IH) and enhance endothelialization in the fabrication of next generation cardiovascular device technology.
Collapse
Affiliation(s)
- Noora Naghavi
- UCL Centre for Nanotechnology & Regenerative Medicine, University College London, UK
| | | | | | | | | |
Collapse
|
12
|
Wu J, Chen Q, Liu W, Zhang Y, Lin JM. Cytotoxicity of quantum dots assay on a microfluidic 3D-culture device based on modeling diffusion process between blood vessels and tissues. LAB ON A CHIP 2012; 12:3474-3480. [PMID: 22836595 DOI: 10.1039/c2lc40502d] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
In this work, a novel quantum dot (QD) cytotoxicity assay platform on a microfluidic three-dimensional (3D) culture device via imitating the diffusion process between blood vessels and tissues was developed. The device is composed of a main channel and two sets of cell culture chambers. The cell culture chambers were located at different distances from the main channel and were divided into "close chambers" and "far chambers". HepG2 cells were cultured in an agarose matrix under 3D conditions and kept at high viability for at least three days. Fluorescein sodium and fluorescein isothiocyanate conjugated to bovine serum albumin (FITC-BSA) were used as models to demonstrate the diffusion process between main channel and cell culture chambers. QD cytotoxicity was evaluated by determining cell apoptosis, intracellular reactive oxygen species (ROS) and glutathione (GSH) with specific fluorescence probes. Cell autophagy inhibitor 3-methyladenine (3-MA) could reduce cell apoptosis at low concentrations of QDs, which proves that cell autophagy plays a key role in QD cytotoxicity. The effect of a series of 3-MA solutions on cell apoptosis at QD concentration of 40 μg mL(-1) was investigated, which showed that the percentage of cell apoptosis decreased ∼15% from 0 to 12 mM 3-MA. The device shows potential as a high-throughput, low-cost and time-saving platform and constructs a more vivid biomimetic microenvironment for the QD cytotoxicity study.
Collapse
Affiliation(s)
- Jing Wu
- Beijing Key Laboratory of Microanalytical Method and Instrumentation, Department of Chemistry, Tsinghua University, Beijing, 100084, China
| | | | | | | | | |
Collapse
|
13
|
Jin J, Yang F, Zhang F, Hu W, Sun SB, Ma J. 2, 2'-(Phenylazanediyl) diacetic acid modified Fe3O4@PEI for selective removal of cadmium ions from blood. NANOSCALE 2012; 4:733-736. [PMID: 22189502 DOI: 10.1039/c2nr11481j] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
A water-dispersible and supermagnetic nanocomposite (PAD-PEG-Fe(3)O(4)@PEI) has been successfully synthesized using polyethylenimine (PEI, Mol MW = 10000) coated supermagnetic Fe(3)O(4)-NH(2) which was modified with 2, 2'-(phenylazanediyl) diacetic acid (PAD) through the bridge of poly(ethylene glycol) (PEG, Mol MW = 2000). The average particle size of PAD-PEG-Fe(3)O(4)@PEI was determined by TEM, and was about 50 nm. From magnetic hysteresis cycles for PAD-PEG-Fe(3)O(4)@PEI at room temperature, the saturation magnetization (Ms) was shown to be 58.14 emu g(-1). Inductively coupled plasma spectrometry (ICP) analysis showed that the designed magnetic nanocomposite can remove 98% and 80% of Cd(2+) from water and blood, respectively.
Collapse
Affiliation(s)
- Jun Jin
- Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province and College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, 730000, PR China.
| | | | | | | | | | | |
Collapse
|
14
|
Galvin P, Thompson D, Ryan KB, McCarthy A, Moore AC, Burke CS, Dyson M, Maccraith BD, Gun'ko YK, Byrne MT, Volkov Y, Keely C, Keehan E, Howe M, Duffy C, MacLoughlin R. Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications. Cell Mol Life Sci 2012; 69:389-404. [PMID: 22015612 PMCID: PMC11115117 DOI: 10.1007/s00018-011-0856-6] [Citation(s) in RCA: 66] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2011] [Revised: 09/29/2011] [Accepted: 09/29/2011] [Indexed: 11/25/2022]
Abstract
Nanoparticles (NPs) comprised of nanoengineered complexes are providing new opportunities for enabling targeted delivery of a range of therapeutics and combinations. A range of functionalities can be included within a nanoparticle complex, including surface chemistry that allows attachment of cell-specific ligands for targeted delivery, surface coatings to increase circulation times for enhanced bioavailability, specific materials on the surface or in the nanoparticle core that enable storage of a therapeutic cargo until the target site is reached, and materials sensitive to local or remote actuation cues that allow controlled delivery of therapeutics to the target cells. However, despite the potential benefits of NPs as smart drug delivery and diagnostic systems, much research is still required to evaluate potential toxicity issues related to the chemical properties of NP materials, as well as their size and shape. The need to validate each NP for safety and efficacy with each therapeutic compound or combination of therapeutics is an enormous challenge, which forces industry to focus mainly on those nanoparticle materials where data on safety and efficacy already exists, i.e., predominantly polymer NPs. However, the enhanced functionality affordable by inclusion of metallic materials as part of nanoengineered particles provides a wealth of new opportunity for innovation and new, more effective, and safer therapeutics for applications such as cancer and cardiovascular diseases, which require selective targeting of the therapeutic to maximize effectiveness while avoiding adverse effects on non-target tissues.
Collapse
Affiliation(s)
- Paul Galvin
- Tyndall National Institute, University College Cork, Cork, Ireland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Lobatto ME, Calcagno C, Metselaar JM, Storm G, Stroes ESG, Fayad ZA, Mulder WJM. Imaging the efficacy of anti-inflammatory liposomes in a rabbit model of atherosclerosis by non-invasive imaging. Methods Enzymol 2012; 508:211-28. [PMID: 22449928 DOI: 10.1016/b978-0-12-391860-4.00011-2] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Nanomedicine can provide a potent alternative to current therapeutic strategies for atherosclerosis. For example, the encapsulation of anti-inflammatory drugs into liposomes improves their pharmacokinetics and biodistribution, thereby enhancing bioavailability to atherosclerotic plaques and improving therapeutic efficacy. The evaluation of this type of experimental therapeutics can greatly benefit from in vivo evaluation to assess biological changes, which can be performed by non-invasive imaging techniques, such as ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). Here, we will illustrate the methods for inducing atherosclerosis in a rabbit model, the production of anti-inflammatory liposomes and monitoring of therapeutic efficacy of experimental therapeutics with the above-mentioned imaging techniques.
Collapse
Affiliation(s)
- Mark E Lobatto
- Translational and Molecular Imaging Institute, Mount Sinai School of Medicine, New York, USA
| | | | | | | | | | | | | |
Collapse
|
16
|
Abstract
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality worldwide. New diagnostic and therapeutic strategies are needed to mitigate this public health issue. Advances in nanotechnology have generated innovative strategies for diagnosis and therapy in a variety of diseases, foremost in cancer. Based on these studies, a novel concept referred to as nanomedical theranostics, or the combinatory application of nanoparticulate agents to allow diagnostic therapy, is being explored to enable image-guided, personalized, or targeted treatment. Preclinically, theranostics have been gradually applied to CVD with several interesting and encouraging findings. This article summarizes studies and challenges of nanotheranostic strategies in CVD. It also evaluates nanotheranostic strategies that may potentially be utilized to benefit patients.
Collapse
|
17
|
Lobatto ME, Fuster V, Fayad ZA, Mulder WJM. Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov 2011; 10:835-52. [PMID: 22015921 PMCID: PMC3623275 DOI: 10.1038/nrd3578] [Citation(s) in RCA: 294] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
The use of nanotechnology for medical purposes--nanomedicine--has grown exponentially over the past few decades. This is exemplified by the US Food and Drug Administration's approval of several nanotherapies for various conditions, as well as the funding of nanomedical programmes worldwide. Although originally the domain of anticancer therapy, recent advances have illustrated the considerable potential of nanomedicine in the diagnosis and treatment of atherosclerosis. This Review elaborates on nanoparticle-targeting concepts in atherosclerotic disease, provides an overview of the use of nanomedicine in atherosclerosis, and discusses potential future applications and clinical benefits.
Collapse
Affiliation(s)
- Mark E Lobatto
- Translational and Molecular Imaging Institute, Mount Sinai School of Medicine, One Gustave L. Levy Place, BOX 1234, New York 10029, USA
| | | | | | | |
Collapse
|
18
|
Choi J, Reipa V, Hitchins VM, Goering PL, Malinauskas RA. Physicochemical characterization and in vitro hemolysis evaluation of silver nanoparticles. Toxicol Sci 2011; 123:133-43. [PMID: 21652737 DOI: 10.1093/toxsci/kfr149] [Citation(s) in RCA: 185] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Silver nanomaterials are increasingly being used as antimicrobial agents in medical devices. This study assessed the in vitro hemolytic potential of unbound silver particles in human blood to determine which physical and chemical particle properties contribute to mechanisms of red blood cell (RBC) damage. Four silver particle powders (two nano-sized and two micron-sized) were dispersed in water and characterized using transmission electron microscopy, dynamic light scattering, surface-enhanced Raman spectroscopy, and zeta potential measurement. Particle size and agglomeration were dependent on the suspension media. Under similar conditions to the hemolysis assay, with the particles added to phosphate buffered saline (PBS) and plasma, the size of the nanoparticles increased compared with particles suspended in water alone due to interaction with chloride ions and plasma proteins. To determine hemolysis response, aqueous particle suspensions were mixed with heparinized human blood diluted in PBS for 3.5 h at 37°C. Both nanoparticle preparations were significantly more hemolytic than micron-sized particles at equivalent mass concentrations > 220 μg/ml and at estimated surface area concentrations > 10 cm(2)/ml. The presence or absence of surface citrate on nanoparticles showed no significant difference in hemolysis. However, the aqueous nanoparticle preparations released significantly more silver ions than micron-sized particles, which correlated with increased hemolysis. Although significant size changes occurred to the silver particles due to interaction with media components, the higher level of in vitro hemolysis observed with nanoparticles compared with micron-sized particles may be related to their greater surface area, increased silver ion release, and direct interaction with RBCs.
Collapse
Affiliation(s)
- Jonghoon Choi
- Biochemical Science Division, National Institute of Standards and Technology, Gaithersburg, Maryland 20899, USA
| | | | | | | | | |
Collapse
|